Norcantharidin suppresses cell growth and migration with enhanced anticancer activity of gefitinib and cisplatin in human non-small cell lung cancer cells

Ya Chun Lee, Liang Ming Lee, Chih Hsin Yang, Anya Maan Yuh Lin, Yi Chia Huang, Chia Chi Hsu, Meng Shian Chen, Chin Wen Chi, Pen Hui Yin, Cheng Deng Kuo, Jyh Fei Liao, Hsin Chen Lee

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Norcantharidin is the demethylated analog of cantharidin isolated from blister beetles (Mylabris phalerata Pall.). In this study, we evaluated whether norcantharidin exhibits anticancer effects against the human non-small cell lung cancer cell lines A549 (epidermal growth factor receptor (EGFR) mutation-negative) and PC9 (EGFR mutation-positive). Our results revealed that norcantharidin dose-dependently retards cell growth, arrests cell cycle at G2/M phase, reduces cell migration, and even induces apoptosis at the concentration of 100 μM. Moreover, we found that norcantharidin enhances the anticancer effects of gefitinib and cisplatin. Norcantharidin exhibited similar potency of anticancer effects against the two cell lines with different EGFR mutation status and did not affect EGF-induced EGFR phosphorylation, suggesting that the EGFR signaling may not be the target of norcantharidin. In conclusion, our results suggest that norcantharidin exhibits anticancer effects against non-small cell lung cancer cells in vitro and support its potential as a chemotherapeutic agent for treating non-small cell lung cancer.

Original languageEnglish
Pages (from-to)237-243
Number of pages7
JournalOncology Reports
Volume29
Issue number1
DOIs
Publication statusPublished - Jan 2013
Externally publishedYes

Fingerprint

norcantharidin
Non-Small Cell Lung Carcinoma
Cisplatin
Cell Movement
Epidermal Growth Factor Receptor
Growth
Mutation
Cantharidin
G2 Phase
Beetles
Blister
Cell Cycle Checkpoints
gefitinib
Epidermal Growth Factor
Cell Division

Keywords

  • Epidermal growth factor receptor
  • Lung cancer
  • Norcantharidin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Norcantharidin suppresses cell growth and migration with enhanced anticancer activity of gefitinib and cisplatin in human non-small cell lung cancer cells. / Lee, Ya Chun; Lee, Liang Ming; Yang, Chih Hsin; Lin, Anya Maan Yuh; Huang, Yi Chia; Hsu, Chia Chi; Chen, Meng Shian; Chi, Chin Wen; Yin, Pen Hui; Kuo, Cheng Deng; Liao, Jyh Fei; Lee, Hsin Chen.

In: Oncology Reports, Vol. 29, No. 1, 01.2013, p. 237-243.

Research output: Contribution to journalArticle

Lee, YC, Lee, LM, Yang, CH, Lin, AMY, Huang, YC, Hsu, CC, Chen, MS, Chi, CW, Yin, PH, Kuo, CD, Liao, JF & Lee, HC 2013, 'Norcantharidin suppresses cell growth and migration with enhanced anticancer activity of gefitinib and cisplatin in human non-small cell lung cancer cells', Oncology Reports, vol. 29, no. 1, pp. 237-243. https://doi.org/10.3892/or.2012.2118
Lee, Ya Chun ; Lee, Liang Ming ; Yang, Chih Hsin ; Lin, Anya Maan Yuh ; Huang, Yi Chia ; Hsu, Chia Chi ; Chen, Meng Shian ; Chi, Chin Wen ; Yin, Pen Hui ; Kuo, Cheng Deng ; Liao, Jyh Fei ; Lee, Hsin Chen. / Norcantharidin suppresses cell growth and migration with enhanced anticancer activity of gefitinib and cisplatin in human non-small cell lung cancer cells. In: Oncology Reports. 2013 ; Vol. 29, No. 1. pp. 237-243.
@article{f12b38656e8f4afc9baf0aced5c87396,
title = "Norcantharidin suppresses cell growth and migration with enhanced anticancer activity of gefitinib and cisplatin in human non-small cell lung cancer cells",
abstract = "Norcantharidin is the demethylated analog of cantharidin isolated from blister beetles (Mylabris phalerata Pall.). In this study, we evaluated whether norcantharidin exhibits anticancer effects against the human non-small cell lung cancer cell lines A549 (epidermal growth factor receptor (EGFR) mutation-negative) and PC9 (EGFR mutation-positive). Our results revealed that norcantharidin dose-dependently retards cell growth, arrests cell cycle at G2/M phase, reduces cell migration, and even induces apoptosis at the concentration of 100 μM. Moreover, we found that norcantharidin enhances the anticancer effects of gefitinib and cisplatin. Norcantharidin exhibited similar potency of anticancer effects against the two cell lines with different EGFR mutation status and did not affect EGF-induced EGFR phosphorylation, suggesting that the EGFR signaling may not be the target of norcantharidin. In conclusion, our results suggest that norcantharidin exhibits anticancer effects against non-small cell lung cancer cells in vitro and support its potential as a chemotherapeutic agent for treating non-small cell lung cancer.",
keywords = "Epidermal growth factor receptor, Lung cancer, Norcantharidin",
author = "Lee, {Ya Chun} and Lee, {Liang Ming} and Yang, {Chih Hsin} and Lin, {Anya Maan Yuh} and Huang, {Yi Chia} and Hsu, {Chia Chi} and Chen, {Meng Shian} and Chi, {Chin Wen} and Yin, {Pen Hui} and Kuo, {Cheng Deng} and Liao, {Jyh Fei} and Lee, {Hsin Chen}",
year = "2013",
month = "1",
doi = "10.3892/or.2012.2118",
language = "English",
volume = "29",
pages = "237--243",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Norcantharidin suppresses cell growth and migration with enhanced anticancer activity of gefitinib and cisplatin in human non-small cell lung cancer cells

AU - Lee, Ya Chun

AU - Lee, Liang Ming

AU - Yang, Chih Hsin

AU - Lin, Anya Maan Yuh

AU - Huang, Yi Chia

AU - Hsu, Chia Chi

AU - Chen, Meng Shian

AU - Chi, Chin Wen

AU - Yin, Pen Hui

AU - Kuo, Cheng Deng

AU - Liao, Jyh Fei

AU - Lee, Hsin Chen

PY - 2013/1

Y1 - 2013/1

N2 - Norcantharidin is the demethylated analog of cantharidin isolated from blister beetles (Mylabris phalerata Pall.). In this study, we evaluated whether norcantharidin exhibits anticancer effects against the human non-small cell lung cancer cell lines A549 (epidermal growth factor receptor (EGFR) mutation-negative) and PC9 (EGFR mutation-positive). Our results revealed that norcantharidin dose-dependently retards cell growth, arrests cell cycle at G2/M phase, reduces cell migration, and even induces apoptosis at the concentration of 100 μM. Moreover, we found that norcantharidin enhances the anticancer effects of gefitinib and cisplatin. Norcantharidin exhibited similar potency of anticancer effects against the two cell lines with different EGFR mutation status and did not affect EGF-induced EGFR phosphorylation, suggesting that the EGFR signaling may not be the target of norcantharidin. In conclusion, our results suggest that norcantharidin exhibits anticancer effects against non-small cell lung cancer cells in vitro and support its potential as a chemotherapeutic agent for treating non-small cell lung cancer.

AB - Norcantharidin is the demethylated analog of cantharidin isolated from blister beetles (Mylabris phalerata Pall.). In this study, we evaluated whether norcantharidin exhibits anticancer effects against the human non-small cell lung cancer cell lines A549 (epidermal growth factor receptor (EGFR) mutation-negative) and PC9 (EGFR mutation-positive). Our results revealed that norcantharidin dose-dependently retards cell growth, arrests cell cycle at G2/M phase, reduces cell migration, and even induces apoptosis at the concentration of 100 μM. Moreover, we found that norcantharidin enhances the anticancer effects of gefitinib and cisplatin. Norcantharidin exhibited similar potency of anticancer effects against the two cell lines with different EGFR mutation status and did not affect EGF-induced EGFR phosphorylation, suggesting that the EGFR signaling may not be the target of norcantharidin. In conclusion, our results suggest that norcantharidin exhibits anticancer effects against non-small cell lung cancer cells in vitro and support its potential as a chemotherapeutic agent for treating non-small cell lung cancer.

KW - Epidermal growth factor receptor

KW - Lung cancer

KW - Norcantharidin

UR - http://www.scopus.com/inward/record.url?scp=84872850504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872850504&partnerID=8YFLogxK

U2 - 10.3892/or.2012.2118

DO - 10.3892/or.2012.2118

M3 - Article

C2 - 23128522

AN - SCOPUS:84872850504

VL - 29

SP - 237

EP - 243

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 1

ER -